OMIX010241

1Summary
Title An iPSC-derived CD19/BCMA-targeting CAR-NK therapy induced immune reset in refractory systemic sclerosis
Description This project reports the first clinical application of iPSC-derived, CD19/BCMA dual-targeting CAR-NK cells (QN-139b) for the treatment of severe diffuse cutaneous systemic sclerosis (dcSSc). The allogeneic product was extensively engineered to minimize immunogenicity and enhance in vivo efficacy, with scalable manufacturing enabled by clonal expansion of iPSCs. In the treated patient, QN-139b was well-tolerated and induced profound B cell depletion alongside marked clinical improvements, including reductions in fibrosis and autoantibody levels. Integrated multi-omics and histopathological analyses revealed immune modulation, reversal of fibrosis, and tissue regeneration. These findings position QN-139b as a promising cell-based immunotherapy for treatment-resistant autoimmune diseases.
Organism Homo sapiens
Data Type Expression Profiling
Data Accessibility Controlled-access
BioProject PRJCA040376
Release Date 2025-05-20
Submitter Xiaobing Wang (gale820907@163.com)
Organization Second Affiliated Hospital of Naval Medical University
Submission Date 2025-05-20
2Files & Download

The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.

File ID File Title Number/Samples File Type File Size File Suffix Download
OMIX010241-01 PBMC scRNA-seq at baseline 5 Expression Profiling 53.1 MB zip Unavailable
OMIX010241-02 PBMC scRNA-seq at M1 5 Expression Profiling 87.9 MB zip Unavailable
OMIX010241-03 PBMC scRNA-seq at M2 5 Expression Profiling 67.9 MB zip Unavailable
OMIX010241-04 PBMC scRNA-seq at M3 5 Expression Profiling 70.4 MB zip Unavailable
3Relevant Publications
Paper Title Journal Name Publish Time Accession Citing Type
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis Cell 2025-06 OMIX010240 OMIX010241 Deposit

View All Released Data of OMIX